Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease?

During illness, adaptations of the hypothalamic–pituitary‐thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine‐to‐thyroxine (fT3/fT4) ratio has been linked to non‐response to treatment in a range of diseases, including in biologic‐treated patients with inflammatory bowel disease.

[1]  B. Yan,et al.  High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists , 2022, Scientific reports.

[2]  M. Schott,et al.  The new Roche Elecsys TSH assay conforms with current IFCC C-STFT standards , 2021, Clinical chemistry and laboratory medicine.

[3]  E. Zimlichman,et al.  Sick Euthyroid Syndrome on Presentation of Patients With COVID-19: A Potential Marker for Disease Severity , 2021, Endocrine Practice.

[4]  M. Emoto,et al.  Low Free Triiodothyronine Level as a Predictor of Cardiovascular Events and All-Cause Mortality in Patients Undergoing Hemodialysis: The DREAM Cohort , 2020, Journal of atherosclerosis and thrombosis.

[5]  E. Fliers,et al.  An update on non-thyroidal illness syndrome , 2020, Journal of Endocrinological Investigation.

[6]  L. Guidi,et al.  Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients , 2020, Alimentary pharmacology & therapeutics.

[7]  T. Ahmad,et al.  Incidence and prevalence of inflammatory bowel disease in Devon, UK , 2020, Frontline Gastroenterology.

[8]  J. Barrett,et al.  HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. , 2019, Gastroenterology.

[9]  C. Lees,et al.  IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology , 2019, Gut.

[10]  M. Parkes,et al.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[11]  S. Vermeire,et al.  Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease , 2019, EBioMedicine.

[12]  K. Goumas,et al.  The effect of anti-TNF therapy on thyroid function in patients with inflammatory bowel disease. , 2018, Endocrine journal.

[13]  S. Vermeire,et al.  Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.

[14]  R. Owens,et al.  Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.

[15]  G. Kaplan,et al.  Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.

[16]  B. Kim,et al.  Low T3 syndrome in neuromyelitis optica spectrum disorder: Associations with disease activity and disability , 2016, Journal of the Neurological Sciences.

[17]  T. Shizuma.  Concomitant Thyroid Disorders and Inflammatory Bowel Disease: A Literature Review , 2016, BioMed research international.

[18]  E. Fliers,et al.  Thyroid function in critically ill patients. , 2015, The lancet. Diabetes & endocrinology.

[19]  Gaosi Xu,et al.  An update for the controversies and hypotheses of regulating nonthyroidal illness syndrome in chronic kidney diseases , 2014, Clinical and Experimental Nephrology.

[20]  Mark Gurnell,et al.  Pitfalls in the measurement and interpretation of thyroid function tests☆ , 2013, Best practice & research. Clinical endocrinology & metabolism.

[21]  C. Bernstein,et al.  Epidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and Comorbidities , 2010, The Journal of Rheumatology. Supplement.

[22]  G. Beckett,et al.  Mechanisms behind the non-thyroidal illness syndrome: an update. , 2010, The Journal of endocrinology.

[23]  B. Haugen.  Drugs that suppress TSH or cause central hypothyroidism. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[24]  A. Morelli,et al.  The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[25]  C. Benbassat,et al.  Subacute thyroiditis: Clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005 , 2007, Journal of endocrinological investigation.

[26]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[27]  C. Bernstein,et al.  The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. , 2005, Gastroenterology.

[28]  M. Bala,et al.  The effects of infliximab maintenance therapy on health-related quality of life , 2003, American Journal of Gastroenterology.

[29]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[30]  Jin-an Zhang,et al.  Non-thyroidal illness syndrome in patients with cardiovascular diseases: A systematic review and meta-analysis. , 2017, International journal of cardiology.

[31]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.